Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Real-world safety and efficacy of belantamab mafodotin in R/R myeloma

Malin Hultcrantz, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the real-world safety and efficacy of belantamab mafodotin in relapsed/refractory multiple myeloma (R/R MM). Despite rates of real-world ocular toxicity being similar to the Phase II DREAMM-2 trial (NCT03525678), patients continued taking belantamab mafodotin. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


GSK Abbvie Amgen BMS